Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 14
Submit an article Journal homepage
247
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

EZH2 inhibitor DZNep blocks cell proliferation of GCB-DLBCL cells by upregulating p16

Panjun Wanga Hematology Department, The Second Affiliated Hospital of Soochow University, Suzhou, PR ChinaORCID Iconhttps://orcid.org/0000-0002-7370-8291
ORCID Icon,
Longjiang Xub Pathology Department, The Second Affiliated Hospital of Soochow University, Suzhou, PR China
,
Yinyin Fanc Clinical Laboratory, The Second Affiliated Hospital of Soochow University, Suzhou, PR China
,
Bingzong Lia Hematology Department, The Second Affiliated Hospital of Soochow University, Suzhou, PR China
,
Ping Chena Hematology Department, The Second Affiliated Hospital of Soochow University, Suzhou, PR China
,
Xiaohui Zhanga Hematology Department, The Second Affiliated Hospital of Soochow University, Suzhou, PR China
,
Yu Suna Hematology Department, The Second Affiliated Hospital of Soochow University, Suzhou, PR China
&
Jinxiang Fua Hematology Department, The Second Affiliated Hospital of Soochow University, Suzhou, PR ChinaCorrespondence[email protected]
 show all
Pages 3370-3377 | Received 11 May 2022, Accepted 18 Sep 2022, Published online: 14 Oct 2022

References

  • Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
  • Carbone A, Gloghini A, Kwong YL, et al. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Ann Hematol. 2014;93(8):1263–1277.
  • Garapaty-Rao S, Nasveschuk C, Gagono A, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol. 2013;20(11):1329–1339.
  • Lu F, Xu H, Wang Q, et al. Inhibition of enhancer of zeste homolog 2 increases the expression of p16 and suppresses the proliferation and migration of ovarian carcinoma cells in vitro and in vivo. Oncol Lett. 2018;15(3):3233–3239.
  • Beguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677–692.
  • Chiappella A, Crombie J, Guidetti A, et al. Are we ready to treat diffuse large B-cell and high-grade lymphoma according to major genetic subtypes? Hemasphere. 2019;3(5):e284.
  • Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood. 2005;106(5):1770–1777.
  • Dobashi A. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Exp Hematop. 2016;56(2):71–78.
  • Crump M. Management of relapsed diffuse large B-cell lymphoma. Hematol Oncol Clin North Am. 2016;30(6):1195–1213.
  • Nowakowski GS, Chiappella A, Gascoyne RD, et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol. 2021;39(12):1317–1328.
  • Moss TJ, Qi Y, Xi L, et al. Comprehensive genomic characterization of upper tract urothelial carcinoma. Eur Urol. 2017;72(4):641–649.
  • Takahashi H, Feuerhake F, Kutok JL, et al. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006;12(11 Pt 1):3265–3271.
  • Kim H, Kim HJ, Kim SH. Diagnostic approach for double-hit and triple-hit lymphoma based on immunophenotypic and cytogenetic characteristics of bone marrow specimens. Ann Lab Med. 2020;40(5):361–369.
  • Ennishi D, Mottok A, Ben-Neriah S, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017;129(20):2760–2770.
  • Schmitz R, Wright GW, Huang DW, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–1407.
  • Koh Y. Genomics of diffuse large B cell lymphoma. Blood Res. 2021;56(S1):S75–S79.
  • Deng Y, Chen X, Huang C, et al. EZH2/bcl-2 coexpression predicts worse survival in diffuse large B-cell lymphomas and demonstrates poor efficacy to rituximab in localized lesions. J Cancer. 2019;10(9):2006–2017.
  • Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360):298–303.
  • Takehara A, Matsui Y. Shortened G1 phase of cell cycle and decreased histone H3K27 methylation are associated with AKT-induced enhancement of primordial germ cell reprogramming. Dev Growth Differ. 2019;61(6):357–364.
  • Lue JK, Amengual JE. Emerging EZH2 inhibitors and their application in lymphoma. Curr Hematol Malig Rep. 2018;13(5):369–382.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.